Episode 3 | Stem Cell Revolution | Mesenchymal Stem Cells, Hope or Hype?

In this episode of Stem Cell Revolution, host Donna Chang engages in a fascinating discussion with Sherry Diers about the groundbreaking world of mesenchymal stem cells (MSCs). The conversation delves into the fundamental differences between MSCs and hematopoietic stem cells, explaining that while hematopoietic stem cells need to be matched to prevent rejection, MSCs are remarkably adaptable and can be sourced from any donor without the same risk of immune rejection.
Sherry and Donna explore how MSCs have shown significant promise in animal trials and numerous clinical studies, citing over 1200 trials with a large number achieving positive results. Despite this, MSCs are still awaiting broader approval in the U.S., leading to a deeper investigation into why many pivotal phase three trials have failed. They discuss the inherent challenges in scaling trials, variability in patient responses, and the difficulties in maintaining cell consistency across large trials.
The conversation also touches on the challenges associated with autologous MSCs, including donor-to-donor variability and the complexities of scaling up production. Sherry and Donna examine the issues surrounding allogeneic MSCs, such as the need for consistent donor cell quality and the difficulties in mass production and preservation.
The episode highlights the impressive safety record of MSCs and their potential in treating various conditions, including immune system disorders and cancer. Donna emphasizes that while MSCs have shown tremendous potential, the focus now is on resolving the technical challenges to fully harness their therapeutic capabilities. The discussion concludes with a hopeful outlook on the future of MSCs, emphasizing their role in treating, preventing, and potentially revolutionizing healthcare.
Tune in to Stem Cell Revolution for an insightful exploration of the cutting-edge field of stem cell therapy and the promising future of MSCs.
Links:
WEBSITE - www.hope.bio
INSTAGRAM - / hope.bio
TWITTER - / hopebiosciences
FACEBOOK - / hopebiosciences

[@bg5760]

Sherry is so kind and thoughtful. I’ve talked with she and Donna…both are so helpful and wonderful people. I hope they are fulfilled, deeply gratified and successful. Thanks 🙏

[@danielw7126]

I'd like to try and get in on that tbi trials.
Who do I contact?
POTS and Central Vestibular Oculomotor Dysfunction both brought on by Stroke in January this year.

[@hopebiosciences]

Unfortunately, that condition would likely not qualify as the enrolling trial is looking for patients with physical head trauma. For more information on the trial, please visit clinicaltrials.gov/study/NCT05951777

[@PRC1020]

I wondered if we would run out of cells if we rely on embryonic stem cells

[@hopebiosciences]

With hope bio's technology, you would quite literally never run out of cells!

[@bg5760]

How do you test for and confirm function of msc’s before you use them? Thanks 🙏

[@hopebiosciences]

The production process has been validated to ensure that what we produce is functional and healthy. When stem cells are made and released for each patient, they are tested at each release. We test them for sterility (bacteria and fungi), mycoplasma, endotoxin, gram staining, cell markers, viability and appearance.

[@anson.meadows]

I was advised by a physician, that stem cells can’t be released from the matrix they are within [in the fat] without using certain enzymes (collagenase) that are illegal to use in the United States, for that purpose. The FDA constitutes these alterations as creating a “drug”…Has this changed?

[@hopebiosciences]

This is correct. The product we make is considered a biological drug in the United States. In a future episode, we will discuss this topic in detail!